OBE2001

OBE2001 is a preclinical **small molecule** drug candidate from **obé** being developed primarily for **obesity**, with broader interest in **type II diabetes** and **cardiovascular diseases**. Based on archived company pipeline materials, OBE2001 is designed to inhibit **APOBEC1**, an intestinally expressed cytidine deaminase implicated in fat absorption biology, with the therapeutic rationale of reducing intestinal fat absorption and improving metabolic disease parameters. The program appears to have remained at the **preclinical** stage, with historical company plans aiming to advance the candidate into early clinical testing in obese patients.